glp·helper
glphelper.com/tirzepatide/florida/altamonte-springs
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Altamonte Springs, FL

Verified Tirzepatide providers in Altamonte Springs, FL. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
23
as of today
§ 02Provider directory: Florida
23 of 23 shown

Find a Tirzepatide provider in Florida.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by Florida city · /tirzepatide/florida/{city}
§ 03Getting Tirzepatide in Altamonte Springs
23 providers · Altamonte Springs, FL

How to get Tirzepatide in Altamonte Springs.

23 GLP-1 prescribers and 7 local resource types are on record for Altamonte Springs, plus 3 nearby towns in the directory.

Prescribers in Altamonte Springs
23 prescribers
23 GLP-1 prescribers in Altamonte Springs, most listed as Family Medicine (13), Internal Medicine (6) and Allergy & Immunology (1). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Apopka (21 providers), Ocoee (26 providers) and Sanford (26 providers).
Around the prescription in Altamonte Springs
7 listed nearby
6 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Altamonte Springs.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Altamonte Springs

Altamonte Springs, Florida has a population of 46,231 people. The adult obesity rate in Altamonte Springs is an age-adjusted estimate of 31.2%, 1.6 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 10.7% of adults in Altamonte Springs. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 22.8% of adults in Altamonte Springs.

of Altamonte Springs adults have obesity
31.2%
diagnosed diabetes
10.7%
no regular physical activity
22.8%

Age-adjusted estimates for Altamonte Springs, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Tirzepatide in Altamonte Springs
6 fitness clubs

The prescription is one part. Here is the rest, in Altamonte Springs.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Altamonte Springs, FL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Genesis Health Clubs, Orlando Sportsplex
FITNESS
4.6 on Google · 1910 reviews
8701 Maitland Summit Blvd
Website
LunaFit Gym
FITNESS
5.0 on Google · 235 reviews
860 N State Rd 434
Website
Shift 110 The Gym
FITNESS
4.9 on Google · 66 reviews
195 S Westmonte Dr #1124
Website
Crunch Fitness - Casselberry
GYM
4.6 on Google · 2184 reviews
1040 FL-436
Website
Crunch Fitness - Altamonte Springs
GYM
4.6 on Google · 1128 reviews
951 N State Rd 434
Website
Crunch Fitness - Maitland, FL
GYM
5.0 on Google · 1102 reviews
701 Maitland Blvd Ste 400
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Adena Dass, RD
RD
Registered dietitian
606 Hattaway Dr
Call 305-902-7937NPI 1841023652
David Guevara Parra, RDN
RD
Registered dietitian
610 Colorado Pl Apt 58
Call 407-373-3561NPI 1437749421
Niurka Martinez, MS, RDN, LDN
RD
Registered dietitian
719 Rodel Cv Ste 2001
Call 407-302-3115NPI 1972365104
Sharon Meitin
RD
Registered dietitian
421 Montgomery Rd
NPI 1144194846
Maria Meza Martinez, MPH, RD
RD
Registered dietitian
608 Fenton Pl Unit 304
Call 407-919-5221NPI 1114877032
Laurie Sirak, RD, LDN
RD
Registered dietitian
175 N Spring Lake Dr
Call 407-697-2455NPI 1871375774
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Florida

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]